Aurora Mirabile, Consultant Medical Oncologist, Head of Head and Neck Cancer Diagnosis and Treatment Section, Division of Otorhinolaryngology, IRCCS Ospedale San Raffaele, shared a post on LinkedIn:
“Honored to be part of this outstanding international collaboration and proud to contribute to the FIERCE-HN Phase III trial, investigating ficlatuzumab plus cetuximab in recurrent/metastatic HPV-negative HNSCC.
Excited to see this work recognized and presented as an ASCO 2026 Poster. Looking forward to the results of this important study and its potential impact on patients with limited treatment options.”
Title: FIERCE-HN: A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of ficlatuzumab (HGF/cMET mAb) in combination with cetuximab in participants with recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC)
Authors: Julie E. Bauman, Lisa F. L. Licitra, Bhumsuk Keam, Neal Akhave, Muh-Hwa Yang, Kevin Joseph Harrington, Christine H. Chung, Sébastien Salas, Aurora Mirabile, Jessica R. Bauman, Nabil F. Saba, Deborah J.L. Wong, Christophe Le Tourneau, Suzy Muggeo, Bo Jin, Paulina Cox, Edgar E. Braendle, Robert I. Haddad
Other articles featuring Aurora Mirabile on OncoDaily.